December 19, 2014
The Japan Pharmaceutical Manufacturers Association (JPMA) has reprimanded Bristol-Myers K.K. over its improper involvement in an investigator-initiated clinical trial on Sprycel (dasatinib), the company’s chronic myeloid leukemia (CML) drug. The JPMA’s board decided on December 18 to issue the reprimand,...read more